Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 70Lymphoma 54Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Hodgkin Disease 26Sarcoma 25Lymphoma, Follicular 25Lymphoma, Non-Hodgkin 24Leukemia 19Burkitt Lymphoma 17Multiple Myeloma 16Endometrial Neoplasms 15Neuroblastoma 14Ovarian Neoplasms 12Carcinoma, Hepatocellular 12Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Mantle-Cell 10Liposarcoma 9Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Leiomyosarcoma 8Histiocytoma, Malignant Fibrous 8Urinary Bladder Neoplasms 7Lymphoma, B-Cell, Marginal Zone 7Hemangiosarcoma 7Fibrosarcoma 7Wilms Tumor 6Triple Negative Breast Neoplasms 6Sarcoma, Synovial 6Neurofibrosarcoma 6

Interventions

pegfilgrastim 3NPI 2358 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Docetaxel 2balugrastim 1Drug Therapy 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Chemotherapy-induced Neutropenia × Doxorubicin × Clear all
NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed
381 enrolled 13 charts

Chemotherapy-induced Neutropenia

NCT03294577 2021-01-15

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 3 Unknown
221 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡